{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:16:31Z","timestamp":1789776991342,"version":"4.0.1"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010653","name":"Masaryk University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010653","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Chronic myeloid leukemia (CML) treatment has been revolutionized over last 20 years because of tyrosine kinase inhibitors (TKIs) and patients with CML now have life expectancy of general population. Chronic TKI treatment may cause adverse effects (AEs) that vary in frequency and severity. Nilotinib shows common AEs with metabolic changes and skin AEs. Here, we present a case report of patient who experienced full psoriasis regression while treated with nilotinib. Dose reductions and an attempt to stop nilotinib treatment resulted in prompt psoriasis reappearance. This is the first documented case of positive effect of nilotinib on psoriasis.<\/jats:p>","DOI":"10.1007\/s00277-025-06228-x","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T03:24:52Z","timestamp":1740713092000},"page":"2001-2004","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Total psoriasis regression in a patient with chronic myeloid leukemia treated using nilotinib"],"prefix":"10.1007","volume":"104","author":[{"given":"Tom\u00e1\u0161","family":"Hor\u0148\u00e1k","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9802-8148","authenticated-orcid":false,"given":"Daniela","family":"\u017d\u00e1\u010dkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji\u0159\u00ed","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"key":"6228_CR1","doi-asserted-by":"crossref","unstructured":"Hughes TP, Ross DM. Moving treatment-free remission into mainstream clinical practice in CML. Blood. 2016. 128(1):17\u201323.","DOI":"10.1182\/blood-2016-01-694265"},{"key":"6228_CR2","doi-asserted-by":"crossref","unstructured":"Berger MG, Pereira B, Rousselot P et al. Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome. Br J Haematol. 2019. 187(3):337\u2013346.","DOI":"10.1111\/bjh.16083"},{"key":"6228_CR3","doi-asserted-by":"crossref","unstructured":"Caldemeyer L, Dugan M, Edwards J, Akard L. Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. Curr Hematol Malig Rep. 2016. 11(2):71\u2009\u2212\u20099.","DOI":"10.1007\/s11899-016-0309-2"},{"key":"6228_CR4","doi-asserted-by":"crossref","unstructured":"Steegmann JL, Cervantes F, le Coutre P et al. Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia. Leuk Lymphoma. 2012. 53(12):2351-61.","DOI":"10.3109\/10428194.2012.695779"},{"key":"6228_CR5","doi-asserted-by":"crossref","unstructured":"Jabbour E, Sasaki K, Haddad FG et al. Low-dose dasatinib 50\u00a0mg\/day versus standard-dose dasatinib 100\u00a0mg\/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis. Am. J. Hematol. 2022. 97(11):1413\u20131814.","DOI":"10.1002\/ajh.26689"},{"key":"6228_CR6","doi-asserted-by":"crossref","unstructured":"Nagai T, Karakawa M, Komine M et al. Development of psoriasis in a patient with chronic myelogenous leukaemia during nilotinib treatment. Eur J Haematol. 2013. 91(3):270\u2013272.","DOI":"10.1111\/ejh.12153"},{"key":"6228_CR7","doi-asserted-by":"crossref","unstructured":"Day E, Waters B, Speigel K et al. Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. Eur J Pharmacol. 2008. 599(1\u20133):44\u201353.","DOI":"10.1016\/j.ejphar.2008.10.014"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06228-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06228-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06228-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T10:10:01Z","timestamp":1745575801000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06228-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":7,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["6228"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06228-x","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,28]]},"assertion":[{"value":"13 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The participant has consented to the submission of the case report to the journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"TH- Novartis (speakers bureau, consultancy), Angelini Pharma (consultancy), DZ- Novartis (speakers bureau, consultancy, member of advisory board), Angelini Pharma (speakers bureau, consultancy), JM- Novartis (research support), BMS (research support).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}